Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: Identification of 1p31-32 deletion as a prognostic factor in myeloma

Leukemia

Volumn 24, Issue 4, 2010, Pages 833-842

  Chng, W J ^a,b,c   Gertz, M A ^d   Chung, T H ^e   Van Wier, S ^a   Keats, J J ^a   Baker, A ^e   Bergsagel, P L ^a   Carpten, J ^e   Fonseca, R ^a  

^a MAYO CLINIC   (United States)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d MAYO CLINIC   (United States)

^e TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Array comparative genomic hybridization; Chromosome 1p; Prognosis

Indexed keywords

DEXAMETHASONE; MELPHALAN;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME 17P; CHROMOSOME 1P; CHROMOSOME 20P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG MEGADOSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

EID: 77950949924     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.21     Document Type: Article

References (37)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111: 2962-2972.
2. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64: 1546-1558.
3. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569-4575.
4. Fonseca R, Van Wier SA, Chng WJ, Ketterling R, Lacy MQ, Dispenzieri A et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006; 20: 2034-2040.
5. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489-3495.
6. Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005; 105: 358-360.
7. Chang H, Qi X, Trieu Y, Xu W, Reader JC, Ning Y et al. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol 2006; 135: 486-491.
8. Chang H, Sloan S, Li D, Zhuang L, Yi QL, Chen CI et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004; 125: 64-68.
9. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002; 118: 1041-1047.
10. Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with total therapy I: interpretation in the context of global gene expression. Blood 2003; 101: 3849-3856.
11. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98: 2229-2238.
12. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003; 101: 1520-1529.
13. Zhan F, Sawyer J, Gupta S, Huang Y, Anaissie E, Xu H et al. Elevated expression of CKS1B at 1q21 is highly correlated with short survival in myeloma. Blood 2004; 104: 77a.
14. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837-2840.
15. Lai JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 1995; 85: 2490-2497.
16. Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999; 113: 73-77.
17. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131-144.
18. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006; 9: 313-325.
19. Largo C, Saez B, Alvarez S, Suela J, Ferreira B, Blesa D et al. Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulin-related chromosome translocations. Haematologica 2007; 92: 795-802.
20. Largo C, Alvarez S, Saez B, Blesa D, Martin-Subero JI, Gonzalez-Garcia I et al. Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma. Haematologica 2006; 91: 184-191.
21. Ahmann GJ, Jalal SM, Juneau AL, Christensen ER, Hanson CA, Dewald GW et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet 1998; 101: 7-11.
22. Walker BA, Leone PE, Jenner MW, Li C, Gonzalez D, Johnson DC et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 2006; 108: 1733-1743.
23. Smadja NV, Fruchart C, Isnard F, Louvet C, Dutel JL, Cheron N et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 1998; 12: 960-969.
24. Chng WJ, Santana-Davila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 2006; 20: 807-813.
25. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N et al. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 2007; 13: 1066-1072.
26. Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM et al. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol 2007; 136: 615-623.
27. Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003; 17: 427-436.
28. Chang H, Ning Y, Qi X, Yeung J, Xu W. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Br J Haematol 2007; 139: 51-54.
29. Dib A, Peterson TR, Raducha-Grace L, Zingone A, Zhan F, Hanamura I et al. Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression. Cell Div 2006; 1: 23.
30. Leone PE, Walker BA, Jenner MW, Chiecchio L, Dagrada G, Protheroe RK et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res 2008; 14: 6033-6041.
31. Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2006; 109: 2276-2284.
32. McAvoy S, Zhu Y, Perez DS, James CD, Smith DI. Disabled-1 is a large common fragile site gene, inactivated in multiple cancers. Genes Chromosomes Cancer 2008; 47: 165-174.
33. Her C, Zhao N, Wu X, Tompkins JD. MutS homologues hMSH4 and hMSH5: diverse functional implications in humans. Front Biosci 2007; 12: 905-911.
34. Lo Vasco VR, Calabrese G, Manzoli L, Palka G, Spadano A, Morizio E et al. Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 2004; 18: 1122-1126.
35. Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, Engel JH et al. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer 2008; 47: 8-20.
36. Linderoth J, Eden P, Ehinger M, Valcich J, Jerkeman M, Bendahl PO et al. Genes associated with the tumour microenvir-onment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 423-432.
37. Dickson BC, Mulligan AM, Zhang H, Lockwood G, O'Malley FP, Egan SE et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 2007; 20: 685-693.